Lanreotide in metastatic enteropancreatic neuroendocrine tumors

Comment

Martyn E Caplin et al. N Engl J Med. 2014.

. 2014 Oct 16;371(16):1556-7.

doi: 10.1056/NEJMc1409757.

No abstract available

Comment on

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Caplin ME, et al. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. N Engl J Med. 2014. PMID: 25014687 Clinical Trial.
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Ozdemir N, Yazici O, Zengin N. Ozdemir N, et al. N Engl J Med. 2014 Oct 16;371(16):1555-6. doi: 10.1056/NEJMc1409757. N Engl J Med. 2014. PMID: 25317882 No abstract available.
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Yang F, Jin C, Fu D. Yang F, et al. N Engl J Med. 2014 Oct 16;371(16):1556. doi: 10.1056/NEJMc1409757. N Engl J Med. 2014. PMID: 25317883 No abstract available.